Company news

Neurizon Therapeutics Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

PharmAust Receives ATO Research & Development Rebate

February 10, 2016

PharmAust completes $3.14m Share Placement oversubscribed

February 10, 2016

PAA: PharmAust Finalises Investment in Oil and Gas Project

February 10, 2016

PAA: Lambouka 3D Seismic Fast Track Interpretation Completed

February 10, 2016

Notice of Annual General Meeting/Proxy Form

February 10, 2016

Non-Renounceable Rights Issue of Options

February 10, 2016

Modification of Clinical Trial in Dogs

February 10, 2016

Lyell McEwin Hospital approved to join PharmAust trial

February 10, 2016

Luke River Project - Exploration Update

February 10, 2016

Luke River Project - Antimony Target

February 10, 2016

Lowest Dosing Cohort with PPL-1 in Dogs Fully Recruited

February 10, 2016

Juniper Pharma Services to reformulate MPL for Phase II

February 10, 2016

Joint Patent with Japanese Corporation now published

February 10, 2016

Initiation of Clinical Trial in Dogs

February 10, 2016

Human Trial Prelim Results Shows Reduction in Tumour Markers

February 10, 2016

Human Cancer Trial Initiation

February 10, 2016

Human Cancer Trial - First Patient Initiates Treatment

February 10, 2016

Half Yearly Report and Accounts

February 10, 2016

GenScript Further Pre-Clinical Validation for Phase II Trial

February 10, 2016

Further Update on New Anti-Cancer Drug PPL-1 in Human Trial

February 10, 2016

First Two Canines Complete Combination Therapy With PPL-1

February 10, 2016

First Dog Shows Suppression of Cancer Marker

February 10, 2016

Final Patient in Cohort Demonstrates Tumour Marker Reduction

February 10, 2016

European High Grade Precious/Base Metal Exploration Project

February 10, 2016

Epichem Gains 51% Interest in JV for New Diabetes Treatment

February 10, 2016

Epichem Awarded Two Year Contract Extension from DNDi

February 10, 2016

Epichem Awarded $1.8M Contract Extension

February 10, 2016

Entitlement Issue Prospectus

February 10, 2016

Consolidation/Split - PAA

February 10, 2016

Completion of Lowest Dose Cohort in Human Cancer Trial

February 10, 2016

Clinical Trial Report Following Phase I Trial

February 10, 2016

Capital Raising and Investment in Oil and Gas Project

February 10, 2016

Capital Raising

February 10, 2016

Cancer Trial Application with Royal Adelaide Hospital

February 10, 2016

Assignment of intellectual property by NewSouth Innovations

February 10, 2016

Approval received to continue with Human Cancer Trial

February 10, 2016

Approval Received for a Clinical Study in Man with PPL-1

February 10, 2016

Approval of Dose Escalation of PPL-1 in Human Trial

February 10, 2016

Approval of Clinical Trial in Dogs

February 10, 2016

Appendix 4E / Full Year Statutory Accounts

February 10, 2016

Appendix 4C Quarterly Report & Company Update

February 10, 2016

Appendix 4C - Quarterly Report and Brief Company Update

February 10, 2016

Appendix 4C - quarterly

February 10, 2016

Accreditation as Animal Research Establishment

February 10, 2016

← Newer news releases

Decks

The 5 newest of 37 decks. Every deck is listed under its year.